| Literature DB >> 35030993 |
Kathrin Seibert1,2, Susanne Stiefler3,4, Dominik Domhoff3,4, Karin Wolf-Ostermann3,4, Dirk Peschke3,4,5.
Abstract
BACKGROUND: Multimorbidity poses a challenge for high quality primary care provision for nursing care-dependent people with (PWD) and without (PWOD) dementia. Evidence on the association of primary care quality of multimorbid PWD and PWOD with the event of a nursing home admission (NHA) is missing. This study aimed to investigate the contribution of individual quality of primary care for chronic diseases in multimorbid care-dependent PWD and PWOD on the duration of ongoing residence at home before the occurrence of NHA.Entities:
Keywords: Dementia; Health claims data; Multi-morbidity; Nursing home; Quality
Mesh:
Year: 2022 PMID: 35030993 PMCID: PMC8759199 DOI: 10.1186/s12877-021-02731-8
Source DB: PubMed Journal: BMC Geriatr ISSN: 1471-2318 Impact factor: 3.921
Fig. 1Flow chart for study population. SHI = Social health insurance, MDK = Medical Service of the Health Funds, NHA = Nursing home admission, IC-10-GM = International Classification of Diseases 10. Revision German Modification, COPD = Chronic obstructive pulmonary disease, PWD = People with dementia, PWOD = People without dementia
Baseline characteristics, 2007, 1st quarter. Absolute and relative frequencies unless otherwise indicated
| People with dementia | People without dementia | Total | |
|---|---|---|---|
| Time under risk in quarters, mean, (SD) | 11.9 (10.8) | 15.6 (12.7) | 14.4 (12.3) |
| Age in years, mean, (SD) | 81.7 (6.9) | 79.6 (7.3) | 80.3 (7.3) |
| Female gender | 3762 (64.0) | 8179 (63.7) | 11,941 (63.8) |
| Level of care | |||
| none | 31 (0.5) | 110 (0.9) | 141 (0.8) |
| I | 3854 (65.6) | 9721 (75.7) | 13,575 (72.5) |
| II | 1762 (30.0) | 2694 (21.0) | 4456 (23.8) |
| III | 229 (3.9) | 312 (2.4) | 541 (2.9) |
| Social network | |||
| Living alone | 2524 (43.0) | 5565 (43.4) | 8089 (43.2) |
| Number of cognitive impairments, mean (SD) | 4.9 (3.4) | 2.3 (2.9) | 3.2 (3.3) |
| Number of functional impairments, mean (SD) | 3.6 (0.8) | 3.5 (0.8) | 3.5 (0.8) |
| Number of prescribed medications, mean (SD) | 6.4 (3.5) | 7.2 (3.9) | 6.9 (3.8) |
| Individuals with potentially inappropriate medication in the elderly | 1735 (29.5) | 4217 (32.9) | 5952 (31.8) |
| Diagnoses | |||
| Asthma | 31 (0.5) | 118 (0.9) | 149 (0.8) |
| COPD | 864 (14.7) | 2591 (20.2) | 3455 (18.5) |
| Hypertension | 5271 (89.7) | 11,699 (91.1) | 16,970 (90.7) |
| Heart failure | 436 (7.4) | 1050 (8.2) | 1486 (7.9) |
| Coronary heart disease | 2552 (43.4) | 5944 (46.3) | 8496 (45.4) |
| Diabetes mellitus type 2 | 3616 (61.5) | 8337 (65.0) | 11,953 (63.9) |
| Osteoarthritis | 1940 (33.0) | 4729 (36.8) | 6669 (35.6) |
| Osteoporosis | 908 (15.5) | 2141 (16.7) | 3049 (16.3) |
| Depression | 1699 (28.9) | 3004 (23.4) | 4703 (25.1) |
SD Standard Deviation, COPD chronic obstructive pulmonary disease
Number of NHA and average duration until NHA by disease group
| Disease group | People with dementia | People without dementia | Total |
|---|---|---|---|
| Number of participants in group | 2732 | 6.314 | 9.046 |
| Number of NHAs (% of individuals in the group) | 1018 (37.3%) | 1507 (23.9%) | 2525 (27.9%) |
| Quarters until NHA, mean (SD) | 8.0 (7.4) | 11.6 (9.3) | 10.1 (8.8) |
| Number of participants in group | 1231 | 2006 | 3237 |
| Number of NHAs (% of individuals in the group) | 482 (39.1%) | 556 (27.7%) | 1038 (32.1%) |
| Quarters until NHA, mean (SD) | 8.9 (8.7) | 13.5 (11.1) | 11.4 (10.3) |
| Number of participants in group | 586 | 1656 | 2242 |
| Number of NHAs (% of individuals in the group) | 175 (29.9%) | 319 (19.3%) | 494 (22.0%) |
| Quarters until NHA, mean (SD) | 8.1 (7.9) | 11.8 (10.3) | 10.5 (9.7) |
| Number of participants in group | 734 | 1136 | 1870 |
| Number of NHAs (% of individuals in the group) | 277 (37.7%) | 320 (28.2%) | 597 (31.9%) |
| Quarters until NHA, mean (SD) | 8.2 (8.3) | 11.9 (10.0) | 10.2 (9.4) |
| Number of participants in group | 348 | 1098 | 1446 |
| Number of NHAs (% of individuals in the group) | 96 (27.6%) | 184 (16.8%) | 280 (19.4%) |
| Quarters until NHA, mean (SD) | 7.9 (6.5) | 10.5 (9.0) | 9.6 (8.3) |
| Number of participants in group | 245 | 627 | 872 |
| Number of NHAs (% of individuals in the group) | 72 (29.4%) | 124 (19.8%) | 196 (22.5%) |
| Quarters until NHA, mean (SD) | 8.3 (7.4) | 9.6 (8.1) | 9.1 (7.8) |
NHA Nursing home admission, SD Standard Deviation, COPD Chronic obstructive pulmonary disease, Diabetes Diabetes mellitus type 2
Results of the time to event analysis among PWD and PWOD with NHA receiving care for chronic conditions
| Disease group | PWD | PWOD | ||||
|---|---|---|---|---|---|---|
| Adjusted HRa | Lower | Upper | Adjusted HRa | Lower | Upper | |
| Medication for hypertension | 1.26 | 0.97 | 1.63 | 1.00 | 0.82 | 1.21 |
| Check of HbA1c | 0.62* | 0.54 | 0.72 | 0.54* | 0.48 | 0.61 |
| Ophthalmological examination | 0.60* | 0.48 | 0.75 | 0.59* | 0.50 | 0.69 |
| Fundus examination | 0.53* | 0.38 | 0.75 | 0.45* | 0.35 | 0.58 |
| Acute inpatient treatment of Diabetes | 2.67* | 1.99 | 3.60 | 2.81* | 2.28 | 3.47 |
| Check of triglycerides and cholesterol | 0.70* | 0.54 | 0.90 | 0.70* | 0.58 | 0.84 |
| Check of serum-creatinine | 0.72* | 0.63 | 0.83 | 0.69* | 0.62 | 0.77 |
| Lower-limb amputation | 3.10* | 1.78 | 5.55 | 2.81* | 1.94 | 4.08 |
| Medication for hypertension | 1.00 | 0.57 | 1.74 | 0.81 | 0.50 | 1.31 |
| Antidepressive medication | 0.98 | 0.80 | 1.21 | 1.37* | 1.15 | 1.63 |
| Medication for hypertension | 0.46 | 0.11 | 1.94 | 0.42 | 0.16 | 1.14 |
| Inhaled medication | 0.54* | 0.35 | 0.84 | 0.79 | 0.61 | 1.02 |
| Non-useful inhaled medication | --b | --b | --b | --b | --b | --b |
| Acute inpatient treatment of COPD | 4.21* | 2.20 | 8.10 | 2.54* | 1.64 | 3.93 |
| Respiratory therapy | 0.86 | 0.43 | 1.72 | 1.15 | 0.79 | 1.68 |
| Influenza vaccination | 0.64 | 0.33 | 1.27 | 0.79 | 0.50 | 1.26 |
| Specific beta-blocker therapy | 0.89 | 0.62 | 1.29 | 0.78 | 0.60 | 1.01 |
| Specific anticholinergic therapy | 0.62 | 0.34 | 1.12 | 1.17 | 0.88 | 1.56 |
| Oral corticosteroids | 1.40 | 0.82 | 2.35 | 0.86 | 0.58 | 1.26 |
| Medication for hypertension | 0.96 | 0.54 | 1.70 | 0.61 | 0.32 | 1.15 |
| Check of HbA1c | 0.62* | 0.47 | 0.82 | 0.49* | 0.38 | 0.62 |
| Ophthalmological examination | 0.53* | 0.34 | 0.81 | 0.57* | 0.41 | 0.80 |
| Fundus examination | 0.40* | 0.20 | 0.77 | 0.56* | 0.35 | 0.89 |
| Acute inpatient treatment of Diabetes | 2.12* | 1.20 | 3.74 | 2.89* | 1.82 | 4.59 |
| Check of triglycerides and cholesterol | 0.80 | 0.52 | 1.23 | 0.56* | 0.36 | 0.85 |
| Check of serum-creatinine | 0.82 | 0.63 | 1.07 | 0.62* | 0.49 | 0.79 |
| Lower-limb amputation | 2.05 | 0.47 | 8.88 | 2.26 | 0.68 | 7.59 |
| Antidepressive medication | 1.28 | 0.99 | 1.66 | 1.30* | 1.02 | 1.64 |
| Medication for hypertension | 1.02 | 0.35 | 2.93 | 0.68 | 0.29 | 1.58 |
| Inhaled medication | 0.80 | 0.43 | 1.50 | 0.80 | 0.57 | 1.11 |
| Non-useful inhaled medication | --b | --b | --b | --b | --b | --b |
| Acute inpatient treatment of COPD | 2.11 | 0.50 | 8.85 | 1.39 | 0.64 | 3.00 |
| Respiratory therapy | 1.69 | 0.87 | 3.27 | 1.47 | 0.93 | 2.33 |
| Influenza vaccination | 0.83 | 0.37 | 1.84 | 0.92 | 0.53 | 1.60 |
| Specific beta-blocker therapy | 0.65 | 0.49 | 1.34 | 0.74 | 0.54 | 1.03 |
| Specific anticholinergic therapy | 1.16 | 0.58 | 2.31 | 0.82 | 0.55 | 1.21 |
| Oral corticosteroids | 0.47 | 0.11 | 1.96 | 0.99 | 0.61 | 1.60 |
| Check of HbA1c | 0.33* | 0.19 | 0.59 | 0.48* | 0.35 | 0.66 |
| Ophthalmological examination | 0.18* | 0.06 | 0.59 | 0.64* | 0.42 | 0.99 |
| Fundus examination | 0.12* | 0.02 | 0.91 | 0.66 | 0.38 | 1.17 |
| Acute inpatient treatment of Diabetes | 0.69 | 0.15 | 3.17 | 2.51* | 1.26 | 5.00 |
| Check of triglycerides and cholesterol | 0.37 | 0.13 | 1.0 | 0.87 | 0.55 | 1.37 |
| Check of serum-creatinine | 0.56* | 0.34 | 0.91 | 0.68* | 0.50 | 0.92 |
| Lower-limb amputation | 2.04 | 0.20 | 20.97 | 0.80 | 0.11 | 5.82 |
| Medication for hypertension | 0.83 | 0.23 | 3.02 | 0.63 | 0.27 | 1.46 |
| Beta-blocker upon heart failure | 1.24 | 0.70 | 2.17 | 1.03 | 0.68 | 1.57 |
| ACE-inhibitor upon heart failure | 0.65 | 0.36 | 1.19 | 1.26 | 0.82 | 1.96 |
| Short acting calcium channel blockers | --b | --b | --b | 0.00 | 0.00 | 0.00 |
| Acute inpatient treatment of heart failure | 1.08 | 0.41 | 2.89 | 1.55 | 0.85 | 2.83 |
| Check of HbA1c | 0.54* | 0.30 | 0.96 | 0.52* | 0.35 | 0.76 |
| Ophthalmological examination | 0.59 | 0.17 | 1.38 | 0.39* | 0.20 | 0.75 |
| Fundus examination | 0.43 | 0.10 | 1.87 | 0.33* | 0.12 | 0.89 |
| Acute inpatient treatment of Diabetes | 2.65 | 0.90 | 7.77 | 3.19* | 1.65 | 6.16 |
| Check of triglycerides and cholesterol | 0.51 | 0.20 | 1.31 | 0.68 | 0.36 | 1.26 |
| Check of serum-creatinine | 0.56 | 0.32 | 1.00 | 0.53* | 0.36 | 0.78 |
| Lower-limb amputation | 1.24 | 0.19 | 8.23 | 2.84 | 0.91 | 8.84 |
NHA Nursing home admission, PWD People with dementia, POWD People without dementia, HR Hazard ratio, CI Confidence interval, COPD Chronic obstructive pulmonary disease, Diabetes Diabetes mellitus type 2
*Significance level alpha < 0.05
aAdjusted for 9 individual-level covariates: age, sex, level of care, direct social network, number of cognitive impairments, number of functional impairments, osteoarthritis, osteoporosis, Charlson comorbidity index
bno results determined due to small number of participants in the numerator of the indicator